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Abstract
Background. Poor ultrafiltration is associated with worse
outcomesinperitonealdialysis(PD)patients.Thismightin
part reflect problems associated with salt and water excess.
Increasing the diffusive component of peritoneal sodium
removal using low-sodium PD fluids might have beneficial
effects on blood pressure (BP), thirst and fluid status that
could translate into clinical benefits.
Methods. Using a multicentre, prospective, baseline con-
trolled (1 month), non-randomized intervention (2 months)
design, two novel solutions designed from predictions us-
ing the three-pore model were investigated. In group A
([Na+] = 115 mmol/l), the glucose (G) was increased to
2.0% to compensate for reduced osmolality whereas in
group B ([Na+] = 102 mmol/l), it was unchanged (2.5%).
Both solutions were substituted for one 3- to 5-h exchange
per day and no change was made to the rest of the dialysis
regime.
Results. Ten patients in group A and 15 in group B com-
pleted the study. Both solutions resulted in significant in-
creases (30–50 mmol/dwell) in diffusive sodium removal
during the test exchanges, P < 0.001. Ultrafiltration was
maintained in group A but reduced in group B. Ambula-
torynocturnalmeanBPfellingroupA[93.1±10.6mmHg
(±SD)versus85.1±10.2mmHg,P<0.05],butwasstable
in group B (95.4 ± 9.4 versus 95.1.1 ± 10.7 mmHg, NS).
Thirst reduced independent of appetite and mood in both
groups by 2 months, more markedly in group A. Indices of
fluid status, including TBW by bioimpedance and D dilu-
t i o na l s oi m p r o v e di ng r o u pA ,P < 0.05, whereas weight
increased in group B.
Conclusions. Increasing the diffusive component of
sodium removal whilst maintaining ultrafiltration is asso-
ciated with improvements in BP, thirst and fluid status.
The lack of effect seen with uncompensated low-sodium
dialysate suggests that these benefits cannot be achieved
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by manipulation of dialysate sodium removal alone. These
observations provide valuable information of the design of
future randomized studies to establish the clinical role for
low-sodium dialysis fluids.
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Introduction
As in all types of renal replacement therapy, long-term
maintenance of adequate fluid and electrolyte balance is of
crucial importance for the survival of patients on peritoneal
dialysis (PD). Observational data from large PD cohorts
show that poor peritoneal salt and water removal is as-
sociated with decreased survival, independent of residual
renal function, inflammation andcardiac biomarkers [1–3].
There is also evidence that when the residual renal function
is low, many PD patients become fluid overloaded [4]. It
is likely that volume overload aggravates not only hyper-
tension, but also left ventricular hypertrophy, often present
alreadyatthestartofPD.Saltandwateroverloadmaybethe
result of excess intake, especially when there is increased
thirst, insufficient ultrafiltration (UF), which is the primary
determinant of peritoneal sodium removal in PD [5,6], or
a combination of these. The problem increases with time
on treatment, not only as a consequence of loss of residual
renal function, but also due to changes in peritoneal mem-
brane function and the desire to avoid excessive glucose
exposure [7].
In clinical practice, various strategies are currently used
to manage fluid excess: dietary salt and fluid restriction,
diuretics, anti-hypertensive drugs, icodextrin, addition of
an extra day dwell, and, as a last option, PD combined with
haemodialysis(HD),orswitchtoHD[8].Anotherpossibil-
ity would be to enhance sodium removal during PD. When
usingconventionalPDfluid,wherethe[Na+]∼132mmol/l,
sodium removal is predominantly due to convection and
typically∼10mmolNa+/dlofUFvolumein4h.Increasing
the glucose concentration toobtain more ultrafiltrationwill
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increase absolute sodium removal, but due to aquaporin-
mediated fluid transport, an essential component of healthy
UF, the relative proportion of sodium to fluid removal will
decrease, especially in short exchanges [6]. This gap be-
tween sodium and fluid removal may in part explain the
increased thirst reported by PD patients [9]. Theoretically,
this problem could be improved by designing low-sodium
dialysis solutions so that the sodium removal by diffusion
would be increased, closing the gap between salt and water
losses. However, no such solutions are presently commer-
cially available.
The role of low-sodium dialysis solutions in the man-
agement of hypernatraemia due to the excessive aquaporin-
mediatedultrafiltrationassociatedwiththeshortexchanges
employed in intermittent PD patients was first described by
Ahearn and Nolph [10]. More recently, Nakayama et al.
[11] studied nine patients on CAPD with a dialysis solu-
tion containing Na+ 120 mmol/l in either 1.36% or 2.27%
glucose (G), replacing all four exchanges. Compared to
conventional solutions, sodium removal over a 4-week pe-
riod increased from 38.5 ± 25.8 mmol/day to 85.0 ± 27.5
mmol daily with the low-sodium solutions. All patients
showedasignificantfallinbloodpressure,andtwopatients
dropped out because of hyponatraemia and overhydration.
Nakayamaetal.alsoreportedtheeffectofultra-low-sodium
dialysisfluid([Na+]:98mmol/l)duringCAPDintwostud-
ies [12]. In one of these, the authors used ultra-low-sodium
dialysis fluid in one exchange daily for 7 days in overhy-
drated CAPD patients. There was a significant increase in
sodium removal and UF. Furthermore, mean arterial pres-
sure(MAP)andbodyweight(BW)decreasedsignificantly.
Similarly, increased sodium removal with variable clini-
cal effects has been demonstrated in a number of subse-
quent small-scale investigations of low-sodium solutions
[13–16].
The design of low-sodium solutions needs careful con-
sideration because sodium is osmotically active, so unless
this is compensated there will be a fall in the ultrafiltration
obtainedthatmightbecounter-productive.Computersimu-
lations of sodium removal as a function of dialysate sodium
concentration according to the three-pore model have re-
cently been reviewed [17], and corroborated by clinical ob-
servations [6]. These simulations show how Na+ removal
couldbestrikinglyincreasedbyreducingdialysisfluidNa+
concentration and the effect this would have on net UF
could be predicted. We have used these simulations to de-
sign three possible low-sodium dialysates called ‘DeltaSol-
low/medium/high’intendedtoreplacelow(1.5%),medium
(2.5%) and high (3.9%) standard Gsolutions for once-daily
clinical use. Each would increase the total sodium removal
by 20–30 mmol/day, but the low and high replacement flu-
ids were compensated with an increase in the glucose to
ensure maintained UF, whereas the medium replacement
solution was not. The purpose of this study was to estab-
lish whether our predictions of sodium removal and UF
were valid, establish their safety and investigate whether
the use of these solutions had any effect on BP, thirst
and volume status. In the event, we were unable to re-
cruit sufficient patients to the regular use of the high G
(3.9%) replacement solution to warrant statistical analysis,
so the data presented here are for the low G (compen-
Table 1. The composition with respect to Na and glucose concentrations,
respectively, for Deltasol and Gambrosol
R trio
Solution Group A Group B
(compensated) (uncompensated)
Sodium (mmol/l)
Gambrosol
R  trio 133 132
Deltasol 115 102
Glucose (%)
Gambrosol
R  trio 1.5 2.5
Deltasol 2.0 2.5
sated, group A) and medium G (uncompensated, group B)
solutions.
Methods
Study design: population
This was an open-label, multicentre, prospective interven-
tion study, performed at the University Hospitals of North
Staffordshire (Stoke-on-Trent, UK), Lund and Malm¨ o
(Sweden). The study product (Deltasol-low/medium) was
compared with conventional solution (Table 1) given as a
single 3- to –6-h dwell per day in patients on either CAPD
or APD, using either G or icodextrin in the long dwell.
The patients had to be at least 18 years old, should not
be participating in another interventional study, should not
be pregnant or lactating, should have a technique and pa-
tient survival compatible with the study duration and had
to be able to give their full consent. Patients were excluded
from the study if they had a positive screen for HIV and/or
hepatitis B and C, a 24-h urine volume exceeding 2000
ml, plasma sodium <125 mmol/l on two consecutive read-
ings, low blood pressure (<110 mm systolic pressure) or
postural blood pressure drop. Furthermore, patients who
had a serious illness or injury or an episode of peritonitis
within 1 month prior to the run-in period were excluded.
Approval for the study was granted by the local research
ethics committees as well as the competent authorities in
UnitedKingdomandSweden.Allsubjectsprovidedwritten
informed consent.
Study design: intervention
After giving informed consent the patients were stabilized
on their normal regime for 1 month (T1–T0). Patients not
usually using Gambrosol
R  trio were appropriately trained
and used this for the study exchange during this period.
The Deltasol study period lasted 2 months during which
one bag of Gambrosol
R  trio, a glucose-lactate-containing,
low-GDP fluid, per day was replaced by the Deltasol low-
sodium solution. Patients were allocated into groups A
(low-strength G, compensated) or B (medium-strength G,
uncompensated) according to their baseline prescription as
a major change in G prescription was considered a poten-
tial hazard. As with Gambrosol
R  trio, Deltasol is a three-
compartment bag allowing the constitution of three differ-
ent low-sodium solutions depending on which are mixed
together prior to instillation. In group A, one bag of 1.5%
G Gambrosol
R  trio was replaced with Deltasol constitutedEffects of low-sodium PD fluids on blood pressure, thirst and volume status 1611
from mixing compartments A and C (G = 2.0%, Na+ =
115 mmol/l). In group B, 2.5% G Gambrosol
R  trio was re-
placed with Deltasol by mixing compartments B+C( G=
2.5%, Na+ = 102 mmol/l); see Table 1.
Longitudinal measurements
Following the stabilization period (T0) and at 1 (T1) and
2 months (T2) during the test period, the patients were
assessed by BW, multifrequency bioelectrical impedance
analysis (Xitron and Tanita instruments, respectively,
seebelow).Totalbodywater(TBW)wasfurtherdetermined
by deuterium oxide (D2O) dilution at T0 and T2. Blood
pressure (BP) was measured by 24-h ambulatory moni-
toring and as office readings. Blood, urine and dialysate
samples were collected for measurements of electrolytes,
glucose, dialysis adequacy, peritoneal membrane transport
characteristicsandresidualrenalfunction(calculatedasthe
mean of urine clearance of urea and creatinine). In a sub-
group of patients, thirst, mood and appetite were assessed
using a specially designed palmtop utilizing an electronic
appetite rating system (EARS) to record serial visual ana-
logue scores (VAS) six times daily previously validated in
PD patients [9]. Changes in anti-hypertensive medication
were prohibited unless needed for patient safety; diuretics
were not changed. Any change in hypertensive medica-
tion was noted. Dialysis prescription remained the same
throughout the study period and identical to the one used
for the stabilization period except for the test bag dwells.
Blood pressure was measured manually with a validated
device at each visit; two measurements were performed
after at least 5 min in sitting position with at least 2
min between the measurements. This was followed by
one measurement in standing position to detect postural
hypotension.
Twenty-four-hour ambulatory blood pressure readings
were recorded using the same device in all three centres
(SpaceLabs Medical, model 90217, Hertfordshire, UK).
Measurements were performed hourly during the entire 24-
h period and divided into day- and nighttime periods with
the nighttime period from 2200 to 0600 h. At least 60%
of the measurements during the entire day or a single pe-
riod had to be properly measured or the measurement was
repeated.
Body composition was determined using two multiple-
frequency bioimpedance devices: the Hydra analyzer
(Model 4200, Xitron Technologies, San Diego, CA, USA)
and Tanita body composition scale (TBF 300 MA, Tanita
UK Ltd, Yiewsley, Middlesex, UK). With the Xitron equip-
ment, measurements were performed using the standard
bipolar technique with electrodes placed on the dorsum
of wrist and anterior aspect of the ankle. The patient was
supine for at least 10 min before measurements without
dialysis fluid present. During the measurements, values for
TBW, extracellular fluid (ECF), intracellular fluid (ICF)
and lean body mass (LBM) were determined by the instru-
ment. The Tanita measurements were performed by having
thepatientsstandingonthescalewiththefeetindirectcon-
tact with the four measuring electrodes and the following
results were recorded: BW, TBW, fat mass (FM), fat-free
mass (FFM), and body mass index (BMI).
Sodium removal and UF volume measurements
Assessing UF volume and sodium removal took careful ac-
count of the problems associated with ‘flush-before-fill’
systems, which due to variable overfill and length of flush
variably over-estimates the UF volume (50–200 ml, and
sodium removal 5–20 mmol) [18,19]. To avoid these er-
rors, bags were weighed before and after instillation and
drainage, respectively. Flush time was recorded and appro-
priate corrections were made.
Analytical methods
All samples were analysed according to current hospital
routines using a Beckman synchronic LX20 auto-analyzer
(Beckman, Colter, Fullerton, CA, USA). Glucose was de-
termined using the hexokinase method. Sodium was mea-
suredusingflamephotometry(Model420FlamePhotome-
ter, Sherwood Scientific Ltd, Cambridge, UK). C-reactive
protein was analysed with an accredited high-sensitivity-
rate turbidimetric method according to routine instructions
at the Clinical Chemistry department at Malm¨ oU n i v e r -
sity Hospital, Malm¨ o, Sweden. TBW was determined by
the D2O dilution. Patients drank 15 or 30 ml of D2O, de-
pending on BW, followed by at least 100 ml of tap water.
Dialysate samples were taken before ingestion and after the
following dwell (>6 h to ensure full equilibration). TBW
was determined from the isotope dilution in equilibrated
dialysate measured by flowing-afterglow mass spectrome-
try; following correction for instilled dialysate volume, this
method allows determination of body water to within 1%
on repeated measures [20].
Calculations
Computersimulationsusingthethree-poremodelwereper-
formed according to the principles given in Rippe et al.
2004 [17] for an average patient, setting A0/ X at 23 000
cm and the mass transfer area coefficient (PS) for Na+
at 6 ml/min.
Total sodium removal was calculated from drained Na+
corrected for flushed Na+ (mmol) minus infused Na+
(mmol). Diffusive (‘free’) Na+ removal is defined by
NaDiff = NaR −
NaP + NaD
2
· S · UFV, (1)
where NaR is the total Na+ removal (in mmol), NaP is
plasma Na+ corrected for plasma water (in mmol/l), NaD is
(mean) dialysate Na+ (in mmol/l), S is the fraction of total
UF volume that normally occurs through small pores (0.6)
according to the three-pore model and UFV is the total UF
volume (in l) during the period of observation (corrected
for flush volume).
Statistical power and analyses
The study was powered to detect significant increases in
free-sodium removal in the test exchanges (primary end-
point, T0 compared to T1). A previous pilot study including
seven patients [16] showed a standard deviation (SD) for
sodium removal per exchange of 12.9 mmol. The expected1612 S. Davies et al.
Table 2. Demographics and treatment modality of all recruited patients
and those completing the study in groups A and B
All recruited patients Group A Group B
(n = 40) (n = 10) (n = 15)
Age (range) 69 (19.6–80.7) 54 60
Gender (M/F) 31/9 8/2 13/2
Height (m) 1.71 (1.43–2.00) 1.71 1.71
APD/CAPD 11/29 3/7 3/12
Icodextrin 4 (40%) 6 (40%)
Average number of 2.5% 1.4 1.3 2.21∗
glucose exchanges
per day
Time on PD (months) 28.5 41.9 19.5
∗P = 0.012 between groups A and B.
free sodium removal determined from computer simula-
tions predicted an increase of free-sodium removal for the
low-, medium- and high-G concentrations of 23.2, 50.4 and
29.2 mmol, respectively. With 80% statistical power using
a two-sided paired t-test, significance P < 0.05, increased
free-sodium removal would be detected with the following
sample sizes: low G, n = 8, medium G, n = 4 and high G
n = 6. We failed to recruit sufficient patients to the high
group, so data were not further analysed. We deliberately
over-recruited to the other groups in order to explore the
potential effects on the secondary clinical measures so that
future randomized studies could be adequately designed.
Data were analysed in an intention to treat basis. Val-
ues are given as mean ± 1 SD, except in figures of re-
peated measures (SEM). Data from 24-h collection showed
considerable variability and are expressed as median val-
uesandanalysedusingbothparametricandnon-parametric
statistics. Comparisons within groups were performed us-
ing paired t-test and between the groups using unpaired
t-test. Analysis of the EARS data was performed using a
three-way mixed ANOVA to compare the therapy groups.
The two repeated factors were ‘visit’ with three levels
(T0,T 1,T 2) and ‘time’ with six levels (measurements taken
every 2 h during the day, a.m., +2, +4, +6, +8, +10 h).
The between-subject (independent) factor was therapy
groupwithtwolevels(A,B).Bonferronicomparisons were
used when appropriate.
Results
Demography, drop-out rate and exclusion
Thedemographic characteristics ofthepatientsrecruited to
the study and those in groups A and B who completed the
study are shown in Table 2. They represented a typical dial-
ysis population: 30% were diabetic, 62.5% had cardiovas-
cular disease and 45% hyperlipidaemia. Underlying diag-
noses were diabetic nephropathy (30%), glomerulonephri-
tis (25%), adult polycystic kidney disease (10%), intersti-
tial/chronic pyelonephritis (10%), nephrosclerosis (7.5%)
and others/unknown (17.5%). Of the 40 patients initially
recruited, 11 left the study, 6 before using the study product
(3 due to peritonitis, 1 wrongly included, 1 due to hypoten-
sion and 1 due to consent withdrawal). Two patients left the
study within 1 month on the study product: 1 due to con-
Table 3. Baseline parameters for patients in groups A and B
Group A (n = 10) B (n = 15)
Systolic office BP (mmHg) 137 ± 18.6 142.3 ± 23.5
Diastolic office BP (mmHg) 87.7 ± 5.9 82.4 ± 13.7
Body weight (kg) 74.7 ± 3.1 82.4 ± 3.4
Body mass index (kg/m2) 25.7 ± 2.7 28.0 ± 4.4
Solute transport (D/Pcreat,h ) 0 . 7 8± 0.1 0.77 ± 0.11
24-h urine volume (ml) 738 ± 612 642 ± 459
24-h urine Na+ loss (mmol) 48.7 ± 38 33.1 ± 35
TBWTanita (l) 40.3 ± 6.6 44.3 ± 6.05
TBWDeuterium (l) 44.6 ± 7.9 47.2 ± 7.5
ECF:ICF ratioXitron 0.92 ± 0.17 0.88 ± 0.15
ThirstEARS (mean of 46.5 ± 18.1 36.8 ± 18.5
baseline score profiles)
HungerEARS (mean of 31.4 ± 15.9 30.6 ± 21.7
baseline score profiles)
MoodEARS (mean of 60.65 ± 17.5 61.6 ± 17.1
baseline score profiles)
Figures denote ±1S D .
There were no significant differences at baseline in any of the parameters
in this table.
sent withdrawal (group A) and 1 due to peritonitis (group
B). Three patients left the study after more than 1 month
on the study product: two due to transplantation and one
consent withdrawal (group B). Twenty-nine patients com-
pleted the entire study with four on the high-G product who
were withdrawn from the analysis. The numbers of patients
at baseline and at each time point by group are shown in
Tables 3 and 4. No patient left the study due to adverse
effects attributable to the study product.
Changes in achieved UF and sodium removal and
comparisons with computer simulated data
At baseline, the total daily peritoneal UF was 355 ± 690 ml
for group A and 855 ± 411 ml in group B (P = 0.002),
Figure 1. As predicted, there was a significant decrease in
UF volume after 1 month in group B (P = 0.034), due to
a fall in UF with the test exchange that was not seen in
group A. There were no significant changes in daily urine
volume or urinary sodium losses over the observation pe-
riod and these were not different between groups (Figure 2
and Table 4). The simulated and achieved total net sodium
removal (NaR) for the test exchanges is shown in Figure 3.
In group A, the achieved NaR for the test dwell was close
to the values predicted by the three-pore model for the
stabilization period (−0.10 ± 11.1 mmol/dwell versus the
three-pore model simulated value of 5 mmol/dwell), al-
though the UF was slightly negative (−69 ml). Delta-
sol markedly improved the NaR that reached 32.4 ±
50.1 mmol/dwell, P = 0.0021, in close agreement with
the three-pore model simulated value (32 mmol/dwell). In
group B, the achieved sodium removal for Gambrosol
R trio
waslowerthanthepredictedvalue(10.6±27.6mmol/dwell
versus a simulated NaR of 37 mmol/dwell), due to a lower
than predicted UF volume (113 ± 24.2 ml). For Deltasol in
group B, the increase in NaR was excellent, being 62.5 ±
26.3 mmol/dwell, P < 0.001, compared to 53 mmol/dwell
in the simulation. The improvement in sodium removal
by Deltasol was nearly entirely (∼90%) due to diffusiveEffects of low-sodium PD fluids on blood pressure, thirst and volume status 1613
Table 4. Longitudinal changes in dialysate and urinary sodium losses, residual renal clearance and plasma sodium
Baseline (T0) 1 month (T1) 2 months (T2)
Group A (n) 10 10 10
Median (inter-quartile range) 24-h dialysate Na+ removal 37.3 (−3.6–74.6) 53.1∗ (28.8–108.7) 53.8∗∗ (18.4–102.8)
Median 24-h urinary Na+ removal 27.7 (0–86) 28.4 (0 –76) 18.0 (0–99)
Residual creatinine clearance (l/week) 11.3 ± 7.1 11.1 ± 6.2 11.6 ± 5.7
Plasma sodium (mmol/l) 137.6 ± 1.9 137.6 ± 3.3 137.2 ± 2.4
Group B (n) 15 15 15
Median (inter-quartile range) 24-h dialysate Na+ removal 52.7 (24.1–99.6) 59.9 (51.9–84.7) 73.5 (58.4–122.8)
Median 24-h urinary Na+ removal 25.8 (0–94) 24.2 (0–121) 28.7 (0–117)
Residual creatinine clearance (l/week) 7.4 ± 5.1 5.9 ± 5.3 8.0 ± 6.2
Plasma sodium (mmol/l) 137.2 ± 3 136.2 ± 3.5 136.3 ± 4.1
∗P = 0.048, ∗∗P = 0.06, P < 0.02 compared to baseline.
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Fig. 1. Twenty-four-hour peritoneal UF at baseline (0 months, T0)a n d
duringDeltasoltreatment(1and2months,T1 andT2)forgroupsA(•)and
B( ). The two groups differed significantly with respect to UF volumes
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Fig. 2. Urine volumes during baseline (0 months) and during Deltasol
treatment (1 and 2 months) for groups A (•)a n dB( ). There were no
significant differences in between groups or as a function of time.
sodium removal for group A and exclusively (∼98%)
due to diffusive sodium removal for group B. These in-
creases in sodium removal from the test exchanges trans-
lated into increases in the total daily peritoneal sodium loss
(see Table 4). For group A, the mean and median increases
in24-hperitonealsodiumremovalwere41.9(P=0.07)and
28.4 mmol (P = 0.048) at T1 and 21.1 (P = 0.049) and
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Fig. 3. Simulated (black bars) and measured (open bars) sodium removal
(mmol/dwell)forbaselinecontrolfluidandlow-sodiumsolutionsatT1 and
T2. For both groups, there was a highly significant increase in measured
sodium removal between baseline, 1 and 2 months (∗P ≤ 0.0002).
14.3 (P = 0.06) at T2, respectively. In group B, mean
and median increases were 13.3 (P = 0.27) and 21 mmol
(P = 0.15) at T1 and 29.5 (P = 0.023) and 32.4 (P = 0.016)
at T2, respectively.
Blood pressure and anti-hypertensive medication
At baseline, there were no differences between groups A
and B in clinic or 24-h blood pressure measurements (P =
0.435). In group A, the nocturnal mean arterial ambula-
tory blood pressure (MAP) fell significantly from T0 to
T2 from 93.1 ± 10.6 mmHg to 85.1 ± 10.2 mmHg (n
= 9, P = 0.045) whereas this was not affected in group
B [95.4 ± 9.4 mmHg at T0 versus 95.1 ± 10.7 mmHg
at T2 (n = 14, P = 0.52)] (see Figure 4). Between-
group differences in nocturnal MAP T1 and T2 became
significantly different (P = 0.019, P = 0.006, respec-
tively). These differences in group A were due to a fall
in both nocturnal systolic (125.4 ± 12.7 mmHg to 113.9 ±
16.4 mmHg, n = 9, P = 0.025) and diastolic blood1614 S. Davies et al.
pressure (77.0 ± 11.5 mmHg to 70.7 ± 8.5 mmHg, n = 9,
P = 0.078). There was a trend towards a reduction in day-
time ambulatory systolic pressure (P = 0.07) and office
MAP (P = 0.068) in group A that was not observed in
group B. A total of 76.5% of the patients were taking anti-
hypertensive medication at the start of the study. Six pa-
tients experienced nine episodes of hypotension necessi-
tating a reduction in their BP medication but this was not
statistically different between groups.
Thirst, appetite and mood evaluation
Analysis of the EARS was undertaken in six patients in
group A and nine from group B. Throughout the study,
group A patients consistently reported greater thirst than
Group B that was not statistically significant. There was
a significant effect of visit on thirst [F(2,20) = 4.86, P <
0.05], with both groups reporting a reduction between T1
and T2 (P < 0.05). This effect was larger in group A (see
Figure 5). There was aneffect of both visit[F(2,20) =4.76,
P < 0.05) and time of day [F(5,50) = 2.98, P < 0.05] on
hunger,withasignificantincreaseoccurringinbothgroups
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Fig. 4. Mean arterial pressure (MAP) during nighttime during baseline
(0 months) and during Deltasol treatment (1 and 2 months) for groups A
(•)a n dB( )( ∗P < 0.05).
at T1 (P < 0.05), but no between-group differences. There
were no effects of group, visit or time of day on mood.
Changes in body composition
The longitudinal changes in body composition by group
are summarized in Table 5. In group A, all the measures
to varying degrees demonstrated a reduction in the body
water content; the multifrequency bioimpedance (Xitron)
indicated that this change was mostly due to a reduction
in the ECF volume. In contrast, there were no signifi-
cant changes in the fluid status of patients in group B, in
which, if anything, there were increases in weight and the
ECF:ICF ratio. We also examined the internal consistency
of the body composition data. For the whole population,
there were significant positive correlations between the
change in TBWD from baseline and the changes in weight
(R = 0.6, P = 0.002), TBWT (R = 0.55, P = 0.004) and
ECFX (R = 0.43, P = 0.04), and the changes in TBWT and
ECFX, (month 1: R = 0.63, P = 0.001; month 2: R = 0.85,
P < 0.001).
Residual renal function, serum albumin, C-reactive
protein and safety parameters
No significant changes were obtained in any of these mea-
surements. Plasma and urinary sodium and residual func-
tion (see Table 4) and osmolality remained stable through-
out the study in all patients. Serum albumin was on average
34.8 ± 3.8 g/l at T0 and 34.7 ± 4.3 g/l at T2. C-reactive
protein was 4.67 ± 0.59 mg/l at T0 and 6.01 ± 1.25 mg/l
at T2. There were no significant within-group differences
observed.
Discussion
This study used computer simulations to design and then
clinically test two novel low-sodium dialysis solutions.
There was a strong agreement between the simulations
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Table 5. Changes in body composition—mean difference (±95% CI)
Month 1 P-value Month 2 P-value
Group A (n)1 0 1 0
Weight (kg) −0.27 (+0.68, −1.2) 0.53 −0.47 (+0.32, −1.3) 0.21
TBW (Tanita) (L) −0.81 (−.04, −1.57) 0.04 −0.97 (−0.5, −1.4) 0.001
TBW (Xitron) (L) −0.89 (−0.04, −1.7) 0.04 −0.04 (+0.71, −1.5) 0.43
TBW (Deuterium) (L) – – −2.3 (−0.34, −4.4) 0.049
ECF (Xitron) −2.5 (+1.2, −6.25) 0.16 −0.61 (−0.1, −1.12) 0.025
ECF/ICF ratio (Xitron) −0.035 (+0.02, −0.09) 0.16 −0.036 (0.00, 0.07) 0.049
Group B (n)1 7 1 5
Weight (kg) −0.02 (+0.72, −.75) 0.96 +0.88 (+1.7, +0.5) 0.04
TBW (Tanita) −0.18 (+0.96, −1.3) 0.73 +0.33 (+1.4, 0.79) 0.54
TBW (Xitron) −0.51 (+0.78, −1.2) 0.53 −0.49 (+1.5, −2.4) 0.61
TBW (D) – – −0.087 (+1.5, −1.6) 0.91
ECF (Xitron) −0.107 (+0.43, −0.65) 0.68 +0.49 (+0.77, −0.67) 0.89
ECF/ICF ratio (Xitron) +0.02 (+0.05, −0.01) 0.23 +0.02 (+0.07, −0.03) 0.32
and observed increase in sodium removal during test
dwells that was predominantly due to an increase in the
diffusive component. This was associated with an in-
crease in the total daily peritoneal sodium removal without
significantly affecting urinary sodium losses, despite the
marked between-patient heterogeneity in daily sodium re-
moval and the associated increase in error when determin-
ing losses from multiple exchanges. There appeared to be
clear differences in the observed effects on the secondary
clinicalendpointsaccordingtowhethertheglucoseconcen-
tration was increased in order to maintain ultrafiltration. In
thecompensatedgroup,therewerereductionsinbloodpres-
sure, ECF and more marked decrease in thirst; no changes
in the clinical measures were observed in the uncompen-
sated group. These observations have implications for our
understanding of membrane physiology, the role of sodium
in controlling blood pressure in PD patients and for the de-
sign of future randomized controlled trials to determine the
clinical role of low-sodium solutions.
Thethree-poremodelremainsthemostpowerfuldescrip-
tor and predictor of peritoneal fluid and solute transport. In
this study, it was used to predict sodium and fluid transport
for a typical PD patient, setting the membrane area param-
eter (A0/ X) at 23 000 cm, equivalent to a D/P creatinine
ratioduringa4-hperitonealequilibrationtestof∼0.72.The
PSvalueforsodiumwasreduced(6ml/min)totakeaccount
of previous observations that suggest it is lower than would
be expected from its molecular weight [17]. When com-
paring the simulations to the observed sodium removal and
ultrafiltration, it is apparent that the predictions of the for-
mer were very close; there was a tendency for the model
to over-predict ultrafiltration, although the expected fall in
ultrafiltration observed in the non-compensated group B
was seen. This relative accuracy in predicting sodium re-
moval, in particular the diffusive component, as compared
to ultrafiltration was also seen in a comprehensive testing
of the model in over 1800 exchanges [6], and would thus
justify the selection of the PS value for sodium.
The actual daily increase in sodium removal observed
(∼30 mmol), regardless of the solution used, is likely to be
clinically significant. There is some confusion in the liter-
ature as to the typical daily sodium removal in PD patients.
This is mainly due to variability in the measurement of net
ultrafiltrationinCAPDpatientsduetothepresenceofover-
fill of dialysate in each bag needed to take into account the
flush before fill procedure and to a lesser extent evapora-
tion [18,19]. This differs by manufacturer and may account
for 50–200 ml per exchange, 200–800 ml per day in a typ-
ical CAPD patient, equivalent to 20–80 mmol of sodium.
The discrepancy in measured sodium intake (∼80 mmol/
day) and removal (180 mmol/day), initially reported by
Asghar et al. can largely be explained by this error [21,
22]. The rather high average daily sodium losses reported
by Ates (180 mmol/day) are also associated with relatively
high reported ultrafiltration; although this might reflect a
high daily salt intake (>11 g/day for the peritoneal com-
ponent alone), the relationship between fluid removal and
mortality reported is much different to more recent studies,
where increased mortality is seen at much lower levels of
ultrafiltration (400–750 ml/day). In one of the centres in
this study (UHNS), regular audit of total daily sodium re-
moval indicated average losses of 70–80 mmol/day (>50%
from urine), although there is a very wide variation. In this
context, anincreaseinperitoneal lossesof30mmolperday
is likely to be clinically significant. Although there is un-
doubtedlyaroleforsensiblesaltrestrictioninPDpatients,it
canseenthatevenarelativelystrictlow-sodiumdietof5ga
day would not be sufficient for some, especially those with
an increased mortality associated with low ultrafiltration in
whom peritoneal losses can be estimated at ∼40–55 mmol/
day (∼3–4 g) as seen in the EAPOS and ADEMEX studies
[1,2].
Theclinicalobservationsinthisstudyappearedtobedif-
ferent according to the type of low-sodium solution used.
The combination of effects seen with the compensated so-
lution that included lower blood pressure, especially for the
nocturnal readings, changes in fluid status in keeping with
a reduction in extracellular water and a greater reduction
in thirst independent of appetite and mood strongly suggest
that benefits can be obtained from increasing the sodium
removal whilst maintaining ultrafiltration in PD patients.
In contrast, the lack of any effects in the uncompensated
groupimpliesthatthesebenefitscannotbeachievedbyma-
nipulation of sodium removal alone. This is a potentially
important clinical message for the management of PD pa-
tients but must be interpreted cautiously. This was not a1616 S. Davies et al.
randomized study and patients were allocated to groups A
and B on the basis of their current treatment regimes and
therefore to some extent were pre-selected. Most of their
baseline characteristics are similar (Tables 2 and 3), except
for the greater peritoneal ultrafiltration in group B reflect-
ing their higher glucose prescription. Interestingly, this did
not translate into significantly higher sodium removal at
baseline,possiblyduetosodiumsievingleadingtoagreater
gap between sodium removal and ultrafiltration. Patients in
group Ahad spent longer ontreatment but werenot propor-
tionately more likely to be on APD or be using icodextrin.
Although these differences were not statistically signifi-
cant, it remains possible that poorly understood or unmea-
sured selection factors such as dietary salt intake that was
not measured independently in this study contributed to the
different clinical effects seen with the two solutions tested.
The lack of effect in group B might have been because the
incremental increase in the peritoneal sodium removal was
lessinthesepatients(35%versus55%ingroupA)andthus
not sufficient to cause a change. In the study of Nakayama
[12], sodium removal was higher than that achieved in the
present study, causing a marked influence on both body
fluid status and BP, even in the absence of glucose compen-
sation of the low-sodium solutions. It is conceivable that an
additional low-sodiumexchange inthepresentstudywould
have caused more clear-cut effects on body fluid status and
BP, even at the price of reduced UF (group B), than those
achieved with only one daily low-sodium exchange.
The rationale behind designing a solution that was not
compensatedwasthatovertimethiswouldleadtodecreased
thirst and thus a lower fluid intake that would more than
make up for the expected loss in ultrafiltration. The level of
thirst measured at baseline was similar to that reported by
Wright using the same methodology [9] and again supports
the impression that PD patients experience increased thirst;
if this were as a result of sodium sieving then low-sodium
solutions by increasing diffusive sodium removal will close
thegapbetweensaltandwaterremovalandthusbeexpected
to be of benefit. Both groups experienced a reduction in
thirst, which appeared more marked in group A, possibly
because they had a higher mean score at baseline. It is of
interest that the effect on thirst did not become significant
until the second month of treatment raising the possibility
that the lack of effect seen in group B was also due to
an insufficiently long observation period; previous studies
have found that the maximal effect of salt restriction may
not be seen for 6 months in haemodialysis patients [23].
Both the solutions investigated in this study appeared
to be safe. Only one patient had to stop the study due to
hypotension and five patients had to reduce their BP medi-
cation. No patients developed hyponatraemia that probably
reflects the decision to use the low-sodium solution for just
one of the exchanges during the 24-h period. There was
no significant fall in residual renal function in either group
suggestingthattheimpactonbloodpressureandfluidstatus
is rather gradual. However, follow-up was just for 2 months
and clearly, longer studies are required to confirm safety.
In conclusion, the present study indicates that it is pos-
sible to improve BP control, fluid status and thirst in PD
patientswiththeuseoflow-sodiumfluids,aslongastheos-
molality is preserved to maintain UF volume. Net sodium
diffusive removal per given glucose load was clearly in-
creased by low-sodium solutions, even moderately exceed-
ing the predictions made by computer modelling such that
net sodium removal using a 2.0% solution exceeded that
removed by a conventional 2.5% dialysate. Finally, over the
observation period, a moderate increase in daily sodium re-
moval was safe with no effects on plasma sodium, residual
renal function or inflammatory markers. These observa-
tions form the basis for future larger randomized controlled
trialstoestablishtheclinicalvalueoflow-sodiumdialysate.
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Short-term effects of bicarbonate/lactate-buffered and conventional
lactate-buffered dialysis solutions on peritoneal ultrafiltration: a
comparative crossover study
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Abstract
Background. This study was designed to compare
the effects of a conventional lactate-based peritoneal
dialysis (PD) solution (D) and a new biocompatible
bicarbonate/lactate-basedsolutionwithalowconcentration
of glucose degradation products (P) on peritoneal ultrafil-
tration (UF) and other peritoneal membrane indices.
Methods. Twenty-six stable, prevalent PD patients were
enrolled in this prospective study. They sequentially un-
derwent 3 months of therapy with the D solution and
3 months with the P solution in a randomized order. Daily,
overnight and 4-h UF on PET were measured and other
peritoneal membrane indices were also assessed using PET
with 2.27% glucose solution.
Results. Twenty-one patients successfully completed the
study. The mean daily peritoneal UF with D was 1324 ±
602 ml and 881 ± 633 ml with P (P < 0.001) and this
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Nephrology, University Medical Center Ljubljana, Zaloˇ ska 2, 1525 Ljubl-
jana, Slovenia. Tel: +386-1-522-3121; Fax: +386-1-522-2228; E-mail:
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lower daily UF of 443 ml (95% CI 275–610 ml) with P was
associatedwithasimilarlylowerdailytotalfluidremovalof
394ml(95%CI210–577ml),asurinevolumedidnotdiffer
between D and P. The decrement in UF with the P solution
was reversible. There were no significant differences in
other peritoneal membrane indices (D/P creatinine, D/D0
glucose,4-hUFatPET,weeklycreatinineclearance,weekly
urea Kt/V) or blood pressure and body weight between
thesolutionswhereascalculatedperitonealfluidabsorption
rate was significantly higher with the P than with the D
solution.
Conclusion. This study shows that the daily UF with
the P solution may be lower than with the D solution.
The mechanism for this short-term and reversible effect
that conceivably reflects differences in biocompatibility
is not clear although our results implicate that the peri-
toneal fluid absorption rate may differ between the two
solutions.
Keywords: bicarbonate/lactate buffered solution;
peritoneal dialysis; PET; prospective study; ultrafiltration
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